Loading clinical trials...

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder

NCT06319170•Teva Branded Pharmaceutical Products R&D LLC

View on ClinicalTrials.gov

Summary

The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine. Another secondary objective is to characterize the pharmacokinetics of ZYPREXA. The planned duration of the study for each participant is 19 weeks.

Detailed Description

All participants received immediate-release ZYPREXA and then were randomized into 1 of 3 extended-release olanzapine formulations.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Body weight \>50 kg and body mass index (BMI) within the range 18.5 to 38.0 kg/m2, inclusive, at the time of screening
•Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the trial until completion of the end of treatment or early termination (ET) visit (ie, nonsmoking participants must agree not to start smoking and participants who smoke will be excluded if they plan to discontinue smoking during the trial
•Agree to the inpatient periods required during the trial period
•Have a current confirmed diagnosis of schizophrenia or schizoaffective disorder according to an evaluation by the Investigator, using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric Association 2013a)
•Have no ongoing or expected significant life events (eg, pending loss of housing, marital status change, long travel abroad, surgery) that could affect trial outcomes throughout the period of trial participation
•Women may be included only if they have a negative serum beta human chorionic gonadotropin (HCG) test result at screening; they are surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal
•Men must be sterile; or if they are potentially of reproductive competence and have sexual relationship with female partners of childbearing potential, they must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 70 days after the last dose administration
•NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria

•Presence or have a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal system, or presence or history of clinically significant immunological, endocrine, or metabolic diseases, neurological or psychiatric disorder(s) (other than schizophrenia)
•History or known risk of narrow-angle glaucoma
•Uncontrolled diabetes
•Major trauma or surgery in the 2 months before screening
•History of malignancy or treatment of malignancy in the last 5 years, excluding resected basal cell or squamous cell carcinoma of the skin
•The participant is a pregnant or lactating woman or plans to become pregnant during the trial or within 70 days after the last dose administration
•Personal or family history of arrhythmia, sudden unexplained death at a young age (before 40 years) in a first-degree relative, long QT syndrome, personal history of syncope, or history of uncontrolled high blood pressure
•NOTE- Additional criteria apply, please contact the investigator for more information

Locations (5)

Teva Investigational Site 15730

Los Alamitos, California, United States

Teva Investigational Site 15727

Hollywood, Florida, United States

Teva Investigational Site 15729

Atlanta, Georgia, United States

Teva Investigational Site 15728

Decatur, Georgia, United States

Teva Investigational Site 15726

Marlton, New Jersey, United States

Key Dates

Start Date

March 28, 2024

Primary Completion Date

January 15, 2025

Completion Date

January 20, 2025

Last Updated

January 26, 2026

Enrollment

106

ACTUAL participants

Conditions

Schizophrenia, Schizoaffective Disorder

Interventions

Olanzapine Extended Release

DRUG

Olanzapine Immediate Release

DRUG

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640

Schizophrenia, Schizoaffective Disorder

View study

COMPLETEDPHASE1

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

View study

COMPLETEDPHASE4

Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions